Kyntra Bio, Inc. (KYNB) Income Statement
KYNB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKYNB revenue and net income
Where KYNB's revenue goes
2025Each bar shows an amount and its share of revenue. KYNB kept 2,848.6% of revenue as net income.
KYNB profit margins
KYNB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −78.3% | −64.2% | −48.4% | −28.4% |
| Gross profit | −58.2% | −63.4% | −48.8% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KYNB quarterly EPS vs estimates
Kyntra Bio beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 9, 2026 (estimate $-3.66).
KYNB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $29.6M | $46.8M | $140.7M | $235.3M | $176.3M | $256.6M | $213.0M | $125.7M | $179.6M |
| Cost of revenue | $556,000 | $15.6M | $4.0M | $20.3M | $449.2M | $8.9M | $1.1M | $235.8M | $196.5M | $187.2M |
| Gross profit | $5.9M | $14.1M | $42.8M | $120.5M | −$213.9M | $167.4M | $255.4M | −$22.9M | −$70.8M | −$7.6M |
| Research & development | $23.5M | $95.7M | $266.5M | $296.8M | $387.0M | $252.9M | $209.3M | $235.8M | $196.5M | $187.2M |
| Sales, general & admin | $27.7M | $49.3M | $86.5M | $124.7M | $123.9M | — | — | $63.8M | $51.8M | $46.0M |
| Total operating expenses | $51.8M | $164.5M | $365.6M | $421.5M | $74.6M | $359.3M | $344.7M | $299.7M | $248.3M | $233.2M |
| Operating income | −$45.9M | −$150.4M | −$322.7M | −$301.0M | −$288.5M | −$191.9M | −$89.3M | −$86.7M | −$122.6M | −$53.7M |
| Interest income | $2.9M | $5.3M | $7.6M | $7.6M | — | — | — | — | — | — |
| Interest expense | $8.8M | $8.2M | $8.1M | $1.4M | $1.1M | $2.4M | $2.9M | $11.0M | $9.7M | $10.7M |
| Income before taxes | −$58.3M | −$153.4M | −$323.2M | −$293.3M | −$289.7M | −$188.9M | −$76.6M | −$86.1M | −$125.9M | −$61.8M |
| Income taxes | −$90,000 | −$269,000 | −$252,000 | $358,000 | $347,000 | $360,000 | $328,000 | $304,000 | $321,000 | −$71,000 |
| Net income | $183.5M | −$47.6M | −$284.2M | −$293.7M | −$290.0M | −$189.3M | −$77.0M | −$86.4M | −$126.2M | −$61.7M |
| EBITDA | −$57.5M | −$142.4M | −$305.2M | −$282.8M | −$333.7M | −$164.3M | −$52.3M | −$68.6M | −$104.7M | −$45.0M |
| EPS (diluted) | $45.47 | −$11.70 | −$56.30 | −$45.38 | −$78.50 | −$37.89 | $2.88 | −$26.26 | −$44.23 | −$25.35 |
| Gross margin | 91.4% | 47.5% | 91.5% | 85.6% | −90.9% | 95.0% | 99.6% | −10.7% | −56.4% | −4.2% |
| Operating margin | −712.7% | −507.8% | −689.5% | −213.9% | −122.6% | −108.8% | −34.8% | −40.7% | −97.6% | −29.9% |
| Net margin | 2,848.6% | −160.6% | −607.3% | −208.7% | −123.3% | −107.4% | −30.0% | −40.6% | −100.4% | −34.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $3.7M | $1.3M | $1.1M | $1.3M | $2.7M | $0 | $46.3M | $998,000 | $25.4M | $27.1M | $40.1M |
| Cost of revenue | $2,000 | $4.1M | −$463,000 | $134,000 | $306,000 | $579,000 | −$20.7M | $5.3M | $32.5M | $57.8M | $5.4M | $4.2M |
| Gross profit | −$1.5M | −$368,000 | $1.7M | $942,000 | $1.0M | $2.2M | −$102.6M | $41.0M | −$31.5M | −$32.5M | $21.7M | $35.9M |
| Research & development | $6.8M | $7.6M | $7.3M | $1.2M | $5.9M | $9.2M | $1.5M | $21.7M | $32.4M | $36.5M | $51.7M | $61.2M |
| Sales, general & admin | $9.3M | $5.9M | $7.2M | $5.3M | $7.1M | $8.1M | $13.3M | $9.4M | — | — | — | — |
| Total operating expenses | $16.1M | $13.4M | $15.8M | $6.3M | $12.7M | $17.0M | −$10.9M | $57.8M | $14.9M | $16.7M | $75.9M | $99.4M |
| Operating income | −$17.6M | −$13.8M | −$14.1M | −$5.4M | −$11.7M | −$14.8M | −$91.7M | −$16.8M | −$46.4M | −$49.2M | −$54.2M | −$63.5M |
| Interest income | $975,000 | $1.1M | $1.3M | $931,000 | $286,000 | $413,000 | $204,000 | $1.5M | — | — | — | — |
| Interest expense | $2.4M | $2.4M | $2.4M | $2.1M | $2.0M | $2.3M | $2.2M | $5.0M | $1.9M | $2.1M | $5.1M | $5.0M |
| Income before taxes | $12.0M | −$15.1M | −$14.6M | −$13.1M | −$13.8M | −$16.8M | −$87.6M | −$17.1M | −$47.4M | −$49.0M | −$56.2M | −$63.5M |
| Income taxes | −$1,000 | $66,000 | −$389,000 | — | −$92,000 | $2,000 | −$52,000 | $12,000 | −$281,000 | $7,000 | $80,000 | $84,000 |
| Net income | $12.0M | −$15.2M | $37.9M | $148.5M | −$7.6M | $4.6M | $18.0M | −$17.1M | −$15.5M | −$32.9M | −$56.2M | −$63.6M |
| EBITDA | −$49.5M | −$12.7M | −$20.9M | −$10.9M | −$11.5M | −$14.2M | −$91.1M | −$12.2M | −$44.7M | −$46.1M | −$49.8M | −$56.8M |
| EPS (diluted) | −$4.68 | −$3.76 | −$3.51 | $49.61 | −$1.88 | $1.25 | $0.18 | $0.37 | −$4.00 | −$8.25 | −$0.57 | −$12.98 |
| Gross margin | — | −9.8% | 136.3% | 87.5% | 77.3% | 78.9% | — | 88.6% | −3,156.5% | −128.0% | 80.1% | 89.4% |
| Operating margin | — | −369.7% | −1,102.0% | −499.1% | −864.9% | −540.1% | — | −36.2% | −4,650.1% | −193.9% | −199.7% | −158.2% |
| Net margin | — | −406.6% | 2,971.3% | 13,798.6% | −564.0% | 169.4% | — | −36.9% | −1,557.5% | −129.8% | −207.2% | −158.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KYNB's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KYNB financial results
In fiscal year 2025 (ended December 31, 2025), Kyntra Bio reported revenue of $6.4 million, down 78.3% from the year before. It had net income of $183.5 million, a net profit margin of 2,848.6%. Diluted earnings per share came to $45.47. Over five years revenue grew at an average rate of −48.4% a year.
See the KYNB stock overview for the latest quote and news, or the KYNB chart for price history and technical indicators.
KYNB income statement FAQ
What is Kyntra Bio's annual revenue?
Kyntra Bio reported total revenue of $6.4 million for fiscal year 2025, which ended on December 31, 2025. That was down 78.3% from $29.6 million the previous year.
Is Kyntra Bio profitable?
Yes. Kyntra Bio reported net income of $183.5 million in fiscal 2025, a net profit margin of 2,848.6%; its operating margin was −712.7%.
What is Kyntra Bio's gross margin?
Kyntra Bio's gross margin was 91.4% in fiscal 2025: for every $100 of revenue, Kyntra Bio kept $91 after the direct cost of its products and services.
How much does Kyntra Bio spend on research and development?
Kyntra Bio spent $23.5 million on research and development in fiscal 2025, 365.2% of revenue.
How fast is Kyntra Bio growing?
Revenue grew −48.4% a year on average over the last five fiscal years, from $176.3 million to $6.4 million.
What are Kyntra Bio's earnings per share?
Kyntra Bio earned $45.47 per diluted share in fiscal 2025, compared with $-11.70 a year earlier.
When will Kyntra Bio report its next earnings?
Kyntra Bio is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes.
When does Kyntra Bio's fiscal year end?
Kyntra Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.